Organization
Celgene Corporation, Warren, United States
4 abstracts
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, AND THE IMPACT OF BASELINE WEIGHT AND BMI ON ACR20 AND HAQ-DI RESPONSE: POOLED RESULTS FROM 3 PHASE 3, RANDOMIZED, CONTROLLED TRIALS Org: Celgene Corporation, Warren, United States,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR: IMPROVEMENTS IN NAIL AND SCALP PSORIASIS AND PSORIASIS AREA AND SEVERITY INDEX IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS (ESTEEM 1 AND 2) Org: Probity Medical Research, Waterloo, Canada, Bakersfield Dermatology, Bakersfield, United States, Toulouse University, Hôpital Larrey, Toulouse, France, SKiN Centre for Dermatology, Peterborough, Canada, SCIderm Research Institute and Dermatologikum Hamburg, Hamburg, Germany,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IS ASSOCIATED WITH LONG-TERM (52-WEEK) IMPROVEMENT IN MEASURES OF DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM 3 PHASE 3, RANDOMIZED, CONTROLLED TRIALS Org: University of California San Diego, San Diego, United States, University of Genova, Genova, Italy, Swedish Medical Center and University of Washington School of Medicine, Seattle, United States, Toronto Western Hospital, Toronto, Canada, University of Sheffield, Sheffield, United Kingdom,
Abstract
APREMILAST, AN ORAL PHOSPHODIESTERASE 4 INHIBITOR, IN PATIENTS WITH PSORIATIC ARTHRITIS INCLUDING CURRENT SKIN INVOLVEMENT: RESULTS OF A PHASE 3, RANDOMIZED, CONTROLLED TRIAL Org: University of Massachusetts Medical School, Worcester, United States, INIBIC-Hospital Universitario A Coruña, Galicia, Spain, Bakersfield Dermatology, Bakersfield, United States, Celgene Corporation, Warren, United States, University Hospital Southampton, Southampton, United Kingdom,